129 related articles for article (PubMed ID: 29061315)
1. Metallothionein prevents doxorubicin cardiac toxicity by indirectly regulating the uncoupling proteins 2.
Jing L; Yang M; Li Y; Yu Y; Liang B; Cao L; Zhou X; Peng S; Sun Z
Food Chem Toxicol; 2017 Dec; 110():204-213. PubMed ID: 29061315
[TBL] [Abstract][Full Text] [Related]
2. Zinc-induced metallothionein overexpression prevents doxorubicin toxicity in cardiomyocytes by regulating the peroxiredoxins.
Jing L; Li L; Zhao J; Zhao J; Sun Z; Peng S
Xenobiotica; 2016 Aug; 46(8):715-25. PubMed ID: 26599915
[TBL] [Abstract][Full Text] [Related]
3. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice.
Fu Z; Guo J; Jing L; Li R; Zhang T; Peng S
Toxicol In Vitro; 2010 Sep; 24(6):1584-91. PubMed ID: 20600803
[TBL] [Abstract][Full Text] [Related]
4. JAK2/STAT3 Pathway Mediates Protection of Metallothionein Against Doxorubicin-Induced Cytotoxicity in Mouse Cardiomyocytes.
Rong J; Li L; Jing L; Fang H; Peng S
Int J Toxicol; 2016 May; 35(3):317-26. PubMed ID: 26526549
[TBL] [Abstract][Full Text] [Related]
5. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotection against doxorubicin by metallothionein Is associated with preservation of mitochondrial biogenesis involving PGC-1α pathway.
Guo J; Guo Q; Fang H; Lei L; Zhang T; Zhao J; Peng S
Eur J Pharmacol; 2014 Aug; 737():117-24. PubMed ID: 24858368
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
8. Peroxiredoxins are involved in metallothionein protection from doxorubicin cardiotoxicity.
Jing L; Wu Y; Wu J; Zhao J; Zuo D; Peng S
Eur J Pharmacol; 2011 Jun; 659(2-3):224-32. PubMed ID: 21463615
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity.
Merten KE; Feng W; Zhang L; Pierce W; Cai J; Klein JB; Kang YJ
J Pharmacol Exp Ther; 2005 Dec; 315(3):1314-9. PubMed ID: 16144979
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels.
Wang GW; Kang YJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):938-44. PubMed ID: 10027829
[TBL] [Abstract][Full Text] [Related]
11. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment.
Shuai Y; Guo JB; Peng SQ; Zhang LS; Guo J; Han G; Dong YS
Toxicol Lett; 2007 Apr; 170(1):66-74. PubMed ID: 17382496
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of Shenmai injection on doxorubicin-induced cardiotoxicity via regulation of inflammatory mediators.
Zhang S; You ZQ; Yang L; Li LL; Wu YP; Gu LQ; Xin YF
BMC Complement Altern Med; 2019 Nov; 19(1):317. PubMed ID: 31744501
[TBL] [Abstract][Full Text] [Related]
13. C1qTNF-related protein-6 protects against doxorubicin-induced cardiac injury.
Zheng WF; Zhang SY; Ma HF; Chang XW; Wang H
J Cell Biochem; 2019 Jun; 120(6):10748-10755. PubMed ID: 30719766
[TBL] [Abstract][Full Text] [Related]
14. Nucleolin protects against doxorubicin-induced cardiotoxicity via upregulating microRNA-21.
Sun H; Tong Z; Fang Y; Jiang B; Liang P; Tang Y; Li Y; Wu Y; Xiao X
J Cell Physiol; 2018 Dec; 233(12):9516-9525. PubMed ID: 29968904
[TBL] [Abstract][Full Text] [Related]
15. Metallothionein acts as a cytoprotectant against doxorubicin toxicity.
Kimura T; Fujita I; Itoh N; Muto N; Nakanishi T; Takahashi K; Azuma J; Tanaka K
J Pharmacol Exp Ther; 2000 Jan; 292(1):299-302. PubMed ID: 10604962
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
Wu HY; Kang YJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
[TBL] [Abstract][Full Text] [Related]
17. GCN2 deficiency ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and myocardial oxidative stress.
Wang Y; Lei T; Yuan J; Wu Y; Shen X; Gao J; Feng W; Lu Z
Redox Biol; 2018 Jul; 17():25-34. PubMed ID: 29660505
[TBL] [Abstract][Full Text] [Related]
18. Paradoxically, iron overload does not potentiate doxorubicin-induced cardiotoxicity in vitro in cardiomyocytes and in vivo in mice.
Guenancia C; Li N; Hachet O; Rigal E; Cottin Y; Dutartre P; Rochette L; Vergely C
Toxicol Appl Pharmacol; 2015 Apr; 284(2):152-62. PubMed ID: 25711856
[TBL] [Abstract][Full Text] [Related]
19. Expression of the Cardiac Maintenance and Survival Factor FGF-16 Gene Is Regulated by Csx/Nkx2.5 and Is an Early Target of Doxorubicin Cardiotoxicity.
Wang J; Jin Y; Cattini PA
DNA Cell Biol; 2017 Feb; 36(2):117-126. PubMed ID: 27929351
[TBL] [Abstract][Full Text] [Related]
20. N-3 polyunsaturated fatty acids decrease levels of doxorubicin-induced reactive oxygen species in cardiomyocytes -- involvement of uncoupling protein UCP2.
Hsu HC; Chen CY; Chen MF
J Biomed Sci; 2014 Nov; 21(1):101. PubMed ID: 25407516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
